Eloralintide
A Phase 2 trial measured up to 20% mean weight loss at week 48 (PMID 41207310; checked 24 Aug 2026). Eli Lilly funded the trial (same source and date). The trial assigned 263 people at random (same source and date). Placebo changed by -0.4% (same source and date). Nausea and fatigue were the most common adverse events. A Phase 3 trial is recruiting (NCT07321886; checked 24 Aug 2026).
What names and identifiers belong to Eloralintide?
GSRS displays Eloralintide and lists LY3841136, LY-3841136, AMY-1176, and AMY1176 (GSRS; checked 24 Aug 2026). It assigns CAS 2883634-40-8.
The GSRS record uses ID 73G3354J8W. Its American FDA UNII entry is marked deprecated. This page states that limit.
The drug is a selective amylin receptor agonist. GSRS lists 36 residues in its main peptide chain.
What did the Phase 2 trial measure?
| Week-48 group | Mean weight change | 95% CI | Primary source | Funder | Checked |
|---|---|---|---|---|---|
| Eloralintide group 1 | -9% | -12.6 to -6.3 | PMID 41207310 | Eli Lilly | 24 Aug 2026 |
| Eloralintide group 2 | -12% | -14.9 to -9.8 | PMID 41207310 | Eli Lilly | 24 Aug 2026 |
| Eloralintide group 3 | -18% | -20.7 to -14.5 | PMID 41207310 | Eli Lilly | 24 Aug 2026 |
| Eloralintide group 4 | -20% | -22.7 to -17.5 | PMID 41207310 | Eli Lilly | 24 Aug 2026 |
| Eloralintide escalation group 1 | -20% | -22.7 to -17.0 | PMID 41207310 | Eli Lilly | 24 Aug 2026 |
| Eloralintide escalation group 2 | -16% | -18.6 to -14.1 | PMID 41207310 | Eli Lilly | 24 Aug 2026 |
| Placebo | -0.4% | -2.2 to 1.4 | PMID 41207310 | Eli Lilly | 24 Aug 2026 |
The paper states that Eli Lilly funded the trial. The registry lists 263 people and posts full results under NCT06230523.
What adverse findings did the Phase 2 trial record?
| Group | At risk | Deaths | People with a serious event | People with another event | Left because of an adverse event | Primary source |
|---|---|---|---|---|---|---|
| Placebo | 53 | 0 | 3 | 25 | 2 | NCT06230523 |
| Eloralintide group 1 | 28 | 0 | 3 | 15 | 2 | NCT06230523 |
| Eloralintide group 2 | 24 | 0 | 1 | 12 | 0 | NCT06230523 |
| Eloralintide group 3 | 28 | 0 | 1 | 27 | 1 | NCT06230523 |
| Eloralintide group 4 | 54 | 0 | 3 | 40 | 1 | NCT06230523 |
| Eloralintide escalation group 1 | 24 | 0 | 2 | 20 | 0 | NCT06230523 |
| Eloralintide escalation group 2 | 52 | 0 | 1 | 34 | 2 | NCT06230523 |
| Group | Serious event terms posted by the registry | Primary source | Checked |
|---|---|---|---|
| Placebo | Mastoiditis; Bladder transitional cell carcinoma; Transitional cell carcinoma recurrent; Acute respiratory failure | NCT06230523 | 24 Aug 2026 |
| Eloralintide group 1 | Lymphadenopathy; Atrial flutter; Abortion spontaneous; Suicidal ideation | NCT06230523 | 24 Aug 2026 |
| Eloralintide group 2 | Acute myocardial infarction | NCT06230523 | 24 Aug 2026 |
| Eloralintide group 3 | Multiple sclerosis | NCT06230523 | 24 Aug 2026 |
| Eloralintide group 4 | Cholelithiasis; Guillain-barre syndrome; Thalamic infarction; Acute kidney injury | NCT06230523 | 24 Aug 2026 |
| Eloralintide escalation group 1 | Acute myocardial infarction; Spondylitic myelopathy | NCT06230523 | 24 Aug 2026 |
| Eloralintide escalation group 2 | Diverticulitis meckel's; Small intestinal obstruction | NCT06230523 | 24 Aug 2026 |
The registry's 5% table lists 38 more terms and counts by group (NCT06230523; checked 24 Aug 2026).
| Threshold | Other event terms posted by the registry |
|---|---|
| 5% | Bradycardia; Sinus bradycardia; Visual impairment; Abdominal distension; Constipation; Diarrhoea; Eructation; Faeces soft; Infrequent bowel movements; Nausea; Vomiting; Early satiety; Fatigue; Injection site reaction; Thirst; Covid-19; Influenza; Nasopharyngitis; Prostate infection; Sinusitis; Upper respiratory tract infection; Urinary tract infection; Vulvovaginal mycotic infection; Contusion; Lipase increased; Decreased appetite; Hyperlipidaemia; Arthralgia; Back pain; Dizziness; Headache; Anxiety; Abnormal uterine bleeding; Benign prostatic hyperplasia; Prostatitis; Nasal congestion; Alopecia; Menopause |
| Common event | Group 1 | Group 2 | Group 3 | Group 4 | Escalation 1 | Escalation 2 | Placebo | Source |
|---|---|---|---|---|---|---|---|---|
| Nausea | 11% | 13% | 64% | 33% | 54% | 25% | 14% | PMID 41207310 |
| Fatigue | 0% | 13% | 29% | 43% | 46% | 21% | 12% | PMID 41207310 |
What did the Phase 1 study report?
The Lilly-funded Phase 1 trial included 48 healthy people (PMID 41109426; checked 24 Aug 2026). Nine eloralintide-treated people reported 16 adverse events. Fifteen of the 16 were mild. Two people reported four gut events, including one moderate vomiting event.
At week 4, two single-dose cohorts measured mean weight changes of -2.5% and -4.4% versus +0.6% with placebo. The paper states that all authors were Lilly employees and shareholders.
What does evidence tier B mean here?
Human trials assigned people at random. The entry assigns tier B (checked 24 Aug 2026). Phase 2 tracked weight for 48 weeks. The tier does not set EU status.
What is the recorded EU status?
ENLIGHTEN-1 is a Phase 3 trial recruiting 1,980 people (NCT07321886; checked 24 Aug 2026). Its EU CTIS ID is 2025-523657-34-00.
The EU Commission active-substance index has no entry for Eloralintide, LY3841136, or AMY-1176 (Union Register index; checked 24 Aug 2026). The EU field remains investigational.
When was Eloralintide first observed in a product?
No vial test or market record is linked here (checked 24 Aug 2026). A trial date is not a vial date. The first_observed field stays blank.
What does this register entry cover?
This entry covers the drug and its codes. It has no test result for a vial. No full guide is installed yet.
→ Weight-loss research hub → What can be in a vial → All register entries